(BLCO) Bausch + Lomb - Ratings and Ratios

Bausch + Lomb Corporation is a leading global eye health company specializing in the development, manufacture, and marketing of products designed to protect and enhance vision. With operations in over 20 countries, including the United States, China, Japan, Germany, the United Kingdom, Canada, and others, the company has a strong international presence. It operates through three core segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment offers a comprehensive range of contact lenses, including daily disposables, frequent replacement lenses, and therapeutic lenses for optical correction during healing. Additionally, it provides contact lens care products, eye vitamins, and over-the-counter eye drops for conditions such as allergies, conjunctivitis, dry eyes, and redness relief. The Pharmaceuticals segment focuses on both proprietary and generic drugs for post-operative treatments, as well as for the management of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides advanced medical devices, consumables, and technologies for cataract, corneal, vitreous, and retinal surgeries, including intraocular lenses, phacoemulsification equipment, and surgical instruments. The company distributes its products through a combination of direct sales forces and independent distributors. Founded in 1853, Bausch + Lomb Corporation is headquartered in Vaughan, Canada, and operates as a subsidiary of Bausch Health Companies Inc.

As of the latest data, Bausch + Lomb Corporation (Ticker Symbol: BLCO) is listed on the Toronto Stock Exchange (TO) under the common stock category, with a market capitalization of approximately 5892.59 million CAD. The company falls under the GICS Sub Industry classification of Health Care Equipment. Its stock has shown a recent price of 19.03 CAD, with a 20-day average volume of 2550 shares. The stocks technical indicators reveal an SMA 20 of 17.77, SMA 50 of 20.69, and SMA 200 of 24.00, with an ATR of 0.98, indicating moderate volatility. On the fundamental side, the company reports a forward P/E ratio of 13.14, a P/B ratio of 0.65, and a P/S ratio of 1.23, though its Return on Equity (RoE) is currently negative at -4.90. Further details about the company can be found on its official website: https://www.bausch.com.